US OptionsDetailed Quotes
ANET241213C490000
- 0.51
- 0.000.00%
15min DelayClose Dec 3 16:00 ET
0.00High0.00Low
0.00Open0.51Pre Close0 Volume7 Open Interest490.00Strike Price0.00Turnover0.00%IV336.51%PremiumDec 13, 2024Expiry Date0.00Intrinsic Value100Multiplier-1DDays to Expiry0.51Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma220.33Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Arista Networks Stock Discussion
Sign in to post a comment
$Esperion Therapeutics (ESPR.US)$ $Esperion Therapeutics (ESPR.US)$ Esperion Therapeutics (ESPR) is a biotech company that focuses on developing and commercializing therapies to lower cholesterol, specifically offering the only FDA-approved statin alternatives: NEXLIZET and NEXLETOL for PRIMARY PREVENTION. These drugs are designed for individuals who are statin intolerant or cannot achieve adequate cholesterol lowering with statin...
+4
1
6
This unique biotech $Esperion Therapeutics (ESPR.US)$ Esperion has the only FDA approved statin alternative drugs NEXLIZET & NEXLETOL for Primary Prevention, Statins are a class of prescription drugs that help lower cholesterol levels. They are the most common treatment for high cholesterol, an estimated 21 Million Americans are Statin intolerant and or maxed out on Statin drugs and need additional lowering. Over 71 ...
+2
9
1
4
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
If you have any inquiry, please feel free to contact us via moomoo app-- me-- customer service-- online inquiry, or call our hotline (+65)-63218888. Have a great day! 
Note: The presence of 30 stock picks reflects the reality that not all stocks respond to their press releases immediately. For instance, today’s market activity saw certain high-performing stocks overshadow promising PRs, suggesting that it may take a day, several days, or even a week for the market to fully digest and react. I encourage you to save the watchlist I p...
34
7
6
1
Volume is very high at 3.7k, very liquid. Do take note of assignment risk if drop below 360 at expiry, 360 x 100 shares.
2
$Arista Networks (ANET.US)$ Wild bear
$Arista Networks (ANET.US)$ With all things beating expectation from the quarterly earning report, why is ANET dropping ~7% post market? The market is sometime hard to understand.
2
6
Stanley Druckenmiller says he's ‘licking my wounds’ from selling Nvidia too soon
-Billionaire investor Stanley Druckenmiller told Bloomberg on Wednesday that selling all his Nvidia stock this year was a “big mistake.”
-Nvidia was Druckenmiller's top holding a year ago, but he sold it after the stock tripled in 2023.
-The shares are up another 174% this year, and Druckenmiller has missed much of the continuing rally.
Stanley Druckenmiller is an American billionair...
-Billionaire investor Stanley Druckenmiller told Bloomberg on Wednesday that selling all his Nvidia stock this year was a “big mistake.”
-Nvidia was Druckenmiller's top holding a year ago, but he sold it after the stock tripled in 2023.
-The shares are up another 174% this year, and Druckenmiller has missed much of the continuing rally.
Stanley Druckenmiller is an American billionair...
6
2
No comment yet
Millaai : Are you being trapped and looking for a rescuer everywhere?
Growth Investor27 : Good info, NEXLIZET is a great drug, my brother takes it. ESPR stock is undervalued, should be above $5
Growth Investor27 Millaai : The author has been buying below $2 so your comment is off. This research article has all the due diligence to see, other than the fact Institutions have been heavly buying this year, fintel shows now 74% owned. ESPR is a good investment.
104248191 : please f o
Detached House Millaai : You are wrong. Though short term looks like the price is consolidating, the weekly chart looks promising! So look at the chart to see if it aligns with the fundamentals before criticising others!
View more comments...